INIS
neoplasms
100%
patients
66%
thrombosis
33%
diseases
16%
risks
16%
blood cells
16%
bioassay
16%
bone marrow
16%
clinical trials
16%
animals
16%
morbidity
16%
screening
16%
mortality
16%
pathogenesis
16%
lymphomas
16%
production
16%
therapy
16%
side effects
16%
foundations
16%
drugs
16%
molecules
16%
Pharmacology, Toxicology and Pharmaceutical Science
Myeloproliferative Neoplasm
100%
Clinical Trial
33%
Thrombosis
33%
Drug Resistance
16%
Bone Marrow Disease
16%
High-Throughput Screening
16%
Pleckstrin
16%
Morbidity
16%
Pathogenesis
16%
B Cell Lymphoma
16%
Janus Kinase 2 Inhibitor
16%
Animal
16%
Mortality
16%
Side Effect
16%
Medicine and Dentistry
Patient
50%
Thrombosis
33%
Combination Therapy
33%
Blood Cell
16%
B-Cell Lymphoma
16%
Janus Kinase 2 Inhibitor
16%
Pleckstrin
16%
Pathogenesis
16%
Drug Resistance
16%
High Throughput Screening
16%
Bone Marrow Disease
16%
Bioassay
16%
Morbidity
16%
Mortality
16%
Inpatient
16%
Therapeutic Procedure
16%
Side Effect
16%